AIMS: We studied the relations of lysophosphatidylcholine (lyso-PC) in LDL with serum lipoprotein-associated phospholipase A(2) (Lp-PLA(2)), paraoxonase and homocysteine thiolactonase (HTLase) activities in patients with type 2 diabetes mellitus. METHODS: Lyso-PC was measured by electrospray ionization-liquid chromatography/mass spectrometry. Paraoxonase and HTLase activities were measured with paraoxon and gamma-thiobutyrolactone as substrates, respectively. RESULTS: Serum HTLase and paraoxonase activities were significantly suppressed in diabetic patients (n=96) compared with control (n=25), whereas serum Lp-PLA(2) did not differ in control and diabetic patients. Lyso-PC contents in LDL correlated with serum Lp-PLA(2) activity positively and with serum HTLase activity negatively. Stepwise regression analysis revealed that serum Lp-PLA(2) and HTLase activities independently contributed to lyso-PC contents in LDL. In patients with diabetic nephropathy, lyso-PC contents in LDL were increased with reduced serum HTLase and paraoxonase activities compared with control, while serum Lp-PLA(2) activity did not differ. On the other hand, 3-month treatment with simvastatin reduced both lyso-PC contents in LDL and serum Lp-PLA(2) activity in hypercholesterolemic diabetic patients, while serum HTLase or paraoxonase activities did not change. CONCLUSIONS: Increased lyso-PC contents in LDL were associated with the suppressed HTLase activity, and serum Lp-PLA(2) and HTLase activities may be related to lyso-PC in type 2 diabetic patients.
AIMS: We studied the relations of lysophosphatidylcholine (lyso-PC) in LDL with serum lipoprotein-associated phospholipase A(2) (Lp-PLA(2)), paraoxonase and homocysteine thiolactonase (HTLase) activities in patients with type 2 diabetes mellitus. METHODS:Lyso-PC was measured by electrospray ionization-liquid chromatography/mass spectrometry. Paraoxonase and HTLase activities were measured with paraoxon and gamma-thiobutyrolactone as substrates, respectively. RESULTS: Serum HTLase and paraoxonase activities were significantly suppressed in diabeticpatients (n=96) compared with control (n=25), whereas serum Lp-PLA(2) did not differ in control and diabeticpatients. Lyso-PC contents in LDL correlated with serum Lp-PLA(2) activity positively and with serum HTLase activity negatively. Stepwise regression analysis revealed that serum Lp-PLA(2) and HTLase activities independently contributed to lyso-PC contents in LDL. In patients with diabetic nephropathy, lyso-PC contents in LDL were increased with reduced serum HTLase and paraoxonase activities compared with control, while serum Lp-PLA(2) activity did not differ. On the other hand, 3-month treatment with simvastatin reduced both lyso-PC contents in LDL and serum Lp-PLA(2) activity in hypercholesterolemic diabeticpatients, while serum HTLase or paraoxonase activities did not change. CONCLUSIONS: Increased lyso-PC contents in LDL were associated with the suppressed HTLase activity, and serum Lp-PLA(2) and HTLase activities may be related to lyso-PC in type 2 diabeticpatients.
Authors: Hala O El Mesallamy; Ebtehal El-Demerdash; Lamiaa N Hammad; Hekmat M El Magdoub Journal: Diabetol Metab Syndr Date: 2010-06-30 Impact factor: 3.320
Authors: J Fortunato; V Bláha; J Bis; J Št'ásek; C Andrýs; J Vojáček; B Jurašková; L Sobotka; P Polanský; M Brtko Journal: J Diabetes Res Date: 2014-04-10 Impact factor: 4.011